U.S. Markets closed

Easton Launches www.EcigMarkets.com Ahead of Schedule and Commences Distributorship of Snoop Dog's Product Lines

TORONTO, ON--(Marketwired - Oct 31, 2014) - Easton Pharmaceuticals Inc. ( OTC : EAPH ) announces it has launched www.ecigmarkets.com ahead of schedule and commences distributorship of Snoop Dog's product lines.

On October 7th Easton Pharmaceuticals announced its entry into the Vaporizer, Glassware and E Liquid sector as a complement to its Medical Marijuana initiatives.

On October 22 Easton hired Toronto based Digitalshock Media http://tiefactory.info/ for Development and launch of its vaporizer initiatives and associated SEO and web marketing campaign for all product lines. Digital Shock's other clients include Disney, Coca Cola, Tylenol, Wind Mobile, SEGA and Gameloft. A two week timeline was allotted for website completion.

Today Easton is pleased to announce it has completed its outlined project ahead of original timeline estimates.

Digital Shock CEO, Mr. Thanhda Tie stated, "I'm happy to have completed the website launch ahead of the Christmas shopping season and ahead of the prior stated completion timeline of 2 weeks. We are looking forward to providing our expertise in this sector and to assist Easton in developing a new successful business."

Snoop Dogg, a well-known American rapper and actor has sold over 30 million albums worldwide. His music career began in 1992 when he was discovered by Dr. Dre. He collaborated on Dre's solo debut The Chronic (1992), and on the theme song to the feature film Deep Cover. He is well known and recognized for his advocacy for Medicinal Marijuana legalization.

Easton has acquired a 100% ownership in websites http://www.EcigMarkets.com as well as http://www.420andfriends.com/, its internet business, including its wholesale segments. Easton plans to carry not only their exclusive branded products, celebrity endorsed product lines, but market and distribute premium products.

Easton Pharmaceuticals CEO Carla Pepe commented, "We are committed to speeding up our current product time-lines which has been demonstrated with a fully functional launch in under three weeks from our initial announcement. Our current focus is on gathering and maintaining a confidential patient population database who have current medical marijuana needs. We believe this will be a great value add for our current partners and gives us a head start when we are granted a MMPR License or partner up with a current MMPR Licensed Provider."

Federal Legal Discussions as it relates to Legalization of Medical Marijuana and market Sentiment

Federal law labels marijuana an illegal "controlled substance." And in May of 2014 a unanimous 8-0 ruling, the high court ruled that patients with debilitating diseases who take the drug to relieve their pain would be doing so illegally. "Congress has made a determination that marijuana has no medical benefits worthy of an exception," Justice Clarence Thomas wrote in the opinion.

On October 28th 2014 an opinion signed by three appellate judges, all of whom were appointed by republican presidents, criticized a federal trial judge for returning a man to prison because of his marijuana use. Language in Posner's opinion suggesting that prison is an inappropriate punishment for marijuana. The second reason Posner's opinion may prove significant is that the panel of judges who signed onto it represent a fairly inclusive cross-section of the judiciary. Posner is himself a Reagan appointee who was once considered a conservative.

With the Marijuana spotlight shining bright on the November 4th Elections which will influence lawmakers and voter sentiment, and directly address's Justice Clarence Thomas's opinion as it paralleled the view of Congress. This is seen as significant catalyst for change in policy. It is a known fact that Law makers fall in line with public opinion and sentiment. Legalization of Medical Marijuana at a Federal level would translate directly to the availability of transport of Medical Marijuana for resale in Canada from US growers.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries including medical marijuana. The Company owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues geared towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite and other conditions. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and Vaporizer, Glassware and Eliquid markets through wholly owned websites http://www.EcigMarkets.com as well as http://www.420andfriends.com/. Easton also miantains the exclusive option to purchase up to 50% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique trans-dermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:


Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "hope", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.